Xtant (XTNT) Director John K. Bakewell Receives Stock Award

What Happened
John K. Bakewell, a director of Xtant Medical Holdings, was granted 215,517 deferred stock units (DSUs) on August 15, 2026. The reported grant price is $0.00 (total reported value $0). The DSUs were granted under Xtant’s Amended and Restated 2023 Equity Incentive Plan, will vest on August 15, 2027, and their settlement is deferred to a later date per the DSU award agreement. This was an award/grant (not an open-market purchase or sale).

Key Details

• Transaction date: 2026-08-15; Form 4 filed: 2026-08-18 (filing appears timely).
• Grant: 215,517 DSUs at $0.00 (total $0 reported).
• Shares/units reported after transaction: Form notes 681,087 shares issuable upon settlement of DSUs granted under the plan (per filing footnote).
• Vesting/settlement: These DSUs vest Aug 15, 2027, conditioned on Bakewell remaining a director; settlement of vested shares is deferred to a later date.
• Nature of award: Each DSU represents a contingent right to receive one share of common stock upon settlement.

Context
DSUs are a form of deferred compensation tied to future issuance of common stock; they do not represent immediate stock purchases or sales and do not by themselves indicate the insider is buying or selling in the market. This grant appears to be a routine director equity award for service, subject to continued board service and delayed settlement.